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Abstract
Background: Large DNA-viruses such as herpesvirus and poxvirus encode proteins that target
and exploit the chemokine system of their host. The Kaposi sarcoma- associated herpes virus
(KSHV) encodes three chemokines. Two of these, vCCL2 and vCCL3, target the human
lymphotactin receptor as an antagonist and a selective agonist, respectively. Therefore these virally
endcoded chemokines have the potential to be used as tools in the study of lymphotactin receptor
pathways in murine models.
Results: The activities of vCCL2, vCCL3, human lymphotactin (XCL1) and murine lymphotactin
(mXCL1) were probed in parallel on the human and murine lymphotactin receptor (XCR1 and
mXCR1) using a phosphatidyl-inositol assay. On the human XCR1, vCCL3, mXCL1 and XCL1
acted as agonists. In contrast, only mXCL1 was able to activate the murine lymphotactin receptor.
Using the same assay, vCCL2 was able to block the response using any of the three agonists on the
humane lymphotactin receptor with IC50s of 2–3 nM. However, vCCL2 was unable to block the
response of mXCL1 through the murine lymphotactin receptor.
Conclusion: This study shows that vCCL2 and vCCL3 cannot be used to investigate lymphotactin
receptor pathways in murine models. These results also add vCCL2 and vCCL3 to a growing list
of viral chemokines with known human chemokine receptor targets, which do not target the
corresponding murine receptors. This fits with the observation that viral and endogenous ligands
for the same human chemokine receptor tend to have relatively divergent amino-acid sequences,
suggesting that these viruses have fine-tuned the design of their chemokines such that the action of
the viral encoded chemokines cannot be expected to cross species barriers.
Background
During the last 15 years, more than 40 chemokines have
been identified in the human genome and nearly all have
been characterized pharmacologically as agonists and led
to the identification of 18 signaling 7TM chemokine
receptors [1,2].
Chemokines are 70–80 amino acid proteins with a char-
acteric three-dimensional fold, which are involved in
guiding and activating distinct leukocyte subsets. Chem-
okines can be divided into four sub-families on the basis
of the pattern and number of the conserved cysteine resi-
dues located near their N-terminus, which are involved in
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disulfide binding formation; the CC-, CXC-, CX3C and XC
family, respectively. The XC-chemokines have only one
cysteine in the N-terminus. Chemokines act through 7TM
GPCRs of which we today know ten CC-chemokine recep-
tors (CCR1-10), six CXC-receptors (CXCR1-6), one CX3C-
receptor (CX3CR1) and one XC-receptor (XCR1). The role
played by the lymphotactin receptor (XCR1) in the
immune system is poorly understood.
In the same period, seven chemokines encoded by large
human DNA viruses have been found by genomic
sequence analysis. Most of these have been characterized
and have been found to have different pharmacological
phenotypes as some target multiple receptors, some only
one receptor, some act as agonists, while others act as
antagonists [3-11](Table 1).
Obviously viral encoded chemokines are important in the
study of viral pathogenesis, but they can also be used as
tools in the investigation of specific chemokine receptors.
Blocking of chemokine receptor action is important in
several assays and immunological models studying the
chemokine system. One example is the selective CCR8
antagonist MC148 encoded by the Molluscuum Contagio-
sum Virus [7]. Another example is the broad-spectrum
chemokine antagonist vCCL2 encoded by HHV8, which
blocks a number of chemokine receptors such as CCR1,
CCR2, CCR5, CX3CR1, CXCR4 and the lymphotactin
receptor XCR1 [6,7]. Thus vCCL2 has been shown to
reduce the inflammatory response in small animal mod-
els models [12-15]. However, viral-encoded agonists are
also useful in the investigation of the role of a chemokine
receptor even when the endogenous human ligand has
been identified, because they can have greater potency
and be more stable than their human counterparts. This is
the case for another HHV8 encoded chemokine vCCL3,
which was recently found to have a 10-fold higher
potency than lymphotactin on the human lymphotactin
receptor [10].
Thus HHV8 encodes both the only known high-affinty
lymphotactin receptor antagonist, vCCL2, as well as the
most potent agonist, vCCL3, known to XCR1 (Figure 1).
Therefore both vCCL2 and vCCL3 are valuable tools in
evaluating the role of the lymphotactin receptor. How-
ever, when using animal models it is obviously important
to characterize these proteins on the specific animal
chemokine receptors. Here we report the characterization
of the viral-encoded proteins vCCL2 and vCCL3 on the
murine lymphotactin receptor done in parallel with the
humane XCR1.
Results and discussion
Recently, we reported that the HHV8 encoded chemokine
vCCL3 is a selective agonist of the human lymphotactin
receptor XCR1, while vCCL2, encoded by the same virus,
acts as an antagonist on this same receptor [10].
Agonistic activity on XCR1 and mXCR1
In order to determine whether these two chemokines
encoded by a human virus and acting on a human recep-
tor also were able to target the corresponding murine
receptor we performed phosphatidyl-inositol assays using
a promiscuous chimeric G-protein[16] co-transfected
with either the human XCR1 gene inserted in the
pcDNA3.1 vector or the murine XCR1 gene inserted into
the pTEJ vector. As expected, XCL1, mXCL1 and vCCL3
activated the human lymphotactin receptor in a dose
responsive manner (Figure 2). As reported earlier [10], the
potency of vCCL3 (EC50 = 3.7 nM) was nearly 10-fold
Table 1: Chemokines encoded by human viruses and their human and murine chemokine receptor targets.
Virus Gene Protein human chemokine receptor targets Ref also targeting the corresponding 
murine chemokine receptor
Ref
CMV UL146 vCXCL1 Selective CXCR2 agonist 11 No 20
UL147 vCXCL2 ?
HHV6a U83B vCCL4 Selective CCR2 agonist 9 ?
HHV8 K6 vCCL1 (vMIP-I) Selective CCR8 agonist 3,5,10 Yes 18
K4 vCCL2 (vMIP-II) Broadspectrum chemokine receptor
antagonist
CCR1 6,7 Yes 19
CCR2 6,7 Yes 19
CCR5 6,7 Yes 19
XCR1 7 No This paper
CX3CR1 7 ?
CXCR4 6,7 ?
CCR3 agonist 17 ?
K4.1 vCCL3 (vMIP-III) Selective XCR1 agonist 10 No This paper
MCV MC148 MCC Selective CCR8 antagonist 7 No 18
aThe protein product from the U83 gene of HHV6A has not been included as its signal sequence include a premature stop codon.Virology Journal 2008, 5:50 http://www.virologyj.com/content/5/1/50
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greater than the potency of XCL1 (EC50 = 30 nM, assum-
ing Emax equal to that of vCCL3) on the human XCR1
receptor. Interestingly, murine lymphotactin had a 3-fold
higher potency (EC50 = 11 nM) than human lymphotactin
on the human lymphotactin receptor.
In contrast, only mXCL1 was able to activate the murine
lymphotactin receptor, while vCCL3 and XCL1 were una-
ble to do so (Figure 2). It should be noted that only a rel-
atively high concentration of mXCL1 (100 nM)
consistently generated an IP3 response through the
murine lymphotactin receptor. This observation could be
explained if mXCL1 was not properly folded or was partly
proteolyzed. However, this is unlikely as 1 nM of mXCL1
in all assays was able to activate the human lymphotactin
receptor. To rule out a vector-specific effect, we performed
similar assays using the mXCR1 gene inserted into
pcDNA3.1. However, no difference in results was found
using the two vector constructs (data not shown). The low
potency of mXCL1 on the mXCR1 in the IP3 assay could
also be related to the cell-line used, but again this expla-
nation seems unlikely as we also had difficulties in gener-
ating calcium mobilization responses to mXCL1 in single
clones of L1.2- and 300.19- cells transfected with murine
lymphotactin receptor cDNA, which suggested that
mXCL1 indeed had low potency for the lymphotactin
receptor. A more likely explanation of the poor potency of
mXCL1 for mXCR1 could be that either the extra N-termi-
nal methionine or the lack of glycosylation of the E. Coli-
produced recombinant murine lymphotactin prevented
proper activation of the murine but not the human lym-
photactin receptor.
Antagonistic activity on XCR1 and mXCR1
We next tested whether vCCL2 was able to act as an antag-
onist on the murine and the human lymphotactin recep-
tors. As reported before [10], vCCL2 did block responses
through XCR1 using submaximal doses of either XCL1,
mXCL1 or vCCL3 (Figure 3). As expected the IC50 values
were almost the same no matter which agonist was used
(mXCL1 had an IC50 = 2.1 nM; XCL1 had an IC50 = 3.0 nM
and vCCL3 had an IC50 = 2.8 nM). In contrast, vCCL2 was
unable to inhibit the response of mXCL1 through the
murine lymphotactin receptor (Figure 3).
Virally encoded chemokines and species barriers
Surprisingly, XCL1 could not activate the murine lympho-
tactin receptor although the sequences of mXCL1 and
XCL1 are very similar (60 % identity and 84 % similarity
using BLASTP 2.2.17 at the NCBI website)(Figure 1). In
contrast, vCCL2 and vCCL3 have only 31 and 32 % iden-
tity and 50 and 54 % similarity to XCL1, although all three
ligands target the same receptor. These points are illus-
trated on the left side of Figure 4. XCL1 and mXCL1 are
clustered, whereas vCCL2 and vCCL3 are more distantly
related to XCL1 although they target the same receptor
(right side of Figure 4). As can be seen from Figure 4, it
seems to be a rule that human encoded chemokines acting
on a particular chemokine receptor, cluster with each
other but not with the viral encoded chemokines targeting
the same receptor. There is one exception, vCCL2, which
on the dendrogram in Figure 4 lies in the middle of a clus-
ter of CCR1, CCR2, and CCR5 ligands. However, vCCL2
also targets XCR1, CX3CR1 and CXCR4 and it does not
cluster with the ligands of these receptors.
This sequence divergence between viral and human chem-
okines may explain why human and not viral encoded
chemokines in general are able to cross a species barrier.
Human encoded chemokines are very similar to their
murine counterparts but very dissimilar to the viral
encoded chemokines they share receptor targets with.
Thus one can imagine that a virus during evolution has
picked up an ancestral chemokine gene and optimized it
Alignment of human, murine and viral ligands for the human and the murine lymphotactin receptor Figure 1
Alignment of human, murine and viral ligands for the human and the murine lymphotactin receptor. The upper 
panel shows the primary structure of the two HHV8 encoded chemokines, vCCL2, vCCL3, the human lymphotactin XCL1 and 
the murine lymphotactin mXCL1 aligned using CLUSTALW from Kyoto University Bioinformatics Center. Identical amino 
acids are shown in white on black, whereas similar amino acids are shown in black on light grey. Cysteines are shown in black 
on yellow and presumed disulfide bridges are marked with an asterisk. Likely O-glycosylation sites using the CBS prediction 
server are marked white on blue. The secondary structure of XCL1 as determined by NMR is indicated by the line above the 
alignment [21].ß ß ß X C L V G S E V S D K R T C V L T T Q R L V R K T Y T T E G L R A V K R G L K V C A D Q A W V R D V V R M D R K N R N N M K N A V m X C L  V G T E V L E E S S C V N L Q T Q R L V Q K K T Y W E G A M R A V V K R G L K C A D E A K W V K A A K V D R A R K N M A E V A A v C C L 2 L G A S W H R P D K C C L G Y Q K R L Q V L L W Y T Q L C K G V L K R G R Q V C A D K K D W V K K M Q Q V A R v C C L 3 S G P A T M A S D C C E N L A R L D K L C G W Y W T T V Y C R Q K A V V H G R K V C G A K R R R M E K H E A K R V A R A KVirology Journal 2008, 5:50 http://www.virologyj.com/content/5/1/50
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in a unique way to suit the virus, while retaining the abil-
ity to target the corresponding chemokine receptor of its
host. However, during this process the hijacked chemok-
ine has changed so much that it has lost the ability to cross
species barriers. As seen in Table 1, the CMV encoded
chemokine vCXCL1, the pox virus encoded chemokine
MC148 and, as shown in this paper, the KSHV encoded
chemokines vCCL2 and vCCL3 are not able to target their
corresponding murine receptors, while only vCCL1
encoded by KSHV has retained this ability [3,5-
7,10,11,17-20].
vCCL2 has been used in several in vivo models, especially
in rodent models, as a broad-spectrum chemokine recep-
tor blocker. For example vCCL2 has been shown to reduce
T-cell mediated inflammation in a murine lymphocytic
choriomeningitis model [14], to protect the brain of mice
against cerebral ischemia [15], to reduce inflammation in
a rat model of spinal cord contusion [13] and in a rat
model of glomerulonephritis [12]. The results from this
study suggest that the reduction of inflammation by
vCCL2 in these experiments is not due to inhibition of the
lymphotactin receptor, but must be due to inhibition of
one or more of the CCR1, CCR2, CCR5, CX3CR1 and
CXCR4 receptors.
Conclusion
The chemokines vCCL2 and vCCL3 encoded by KSHV do
not target the murine lymphotactin receptor, although
they act as a high potency antagonist and agonist respec-
tively, on the human lymphotactin receptor. So the only
tool left, for investigating the role of the lymphotactin
receptor pathways in murine models, is the commercially
Inhibition of the human and murine lymphotactin receptor by  the viral antagonist vCCL2 Figure 3
Inhibition of the human and murine lymphotactin 
receptor by the viral antagonist vCCL2. Dose-response 
experiments for inhibition of IP3-turnover by the antagonist 
vCCL2 induced by XCL1 (black square) mXCL1 (black trian-
gle) and vCCL3 (white circle) in COS-7 cells transiently 
transfected with the human and murine lymphotactin recep-
tors XCR1 and mXCR1 and the promiscuous chimeric G-
protein Gqi4myr. All assays were performed in duplicate.
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Activation of the human and murine lymphotactin receptor  by human, murine and viral agonists Figure 2
Activation of the human and murine lymphotactin 
receptor by human, murine and viral agonists. Dose-
response experiments measuring IP3 turnover in COS-7 cells 
transiently transfected with the human and murine lympho-
tactin receptors XCR1 and mXCR1 and the promiscuous 
chimeric G-protein Gqi4myr using increasing concentrations 
of the agonists XCL1 (black square), mXCL1 (black triangle) 
and vCCL3 (white circle). The thin line indicate the EC50 for 
the particular ligand (assuming Emax equal to that of vCCL3). 
All assays were performed in duplicate.
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available recombinant form of murine lymphotactin with
a rather low potency on the mXCR1 receptor. Further-
more, when the findings of this paper are combined with
the results from other studies on the ability of chemokines
encoded by human viruses to target the murine counter-
parts to their human chemokine receptor targets, it can be
concluded that they rarely do so. In contrast, human
encoded chemokines in general are able to cross the spe-
cies barrier and target their corresponding murine chem-
okine receptors.
Amino-acid sequence similarity of human and viral encoded chemokines compared to their chemokine receptor targets Figure 4
Amino-acid sequence similarity of human and viral encoded chemokines compared to their chemokine recep-
tor targets. Left side of the figure is a comparison of the similiarity of the primary protein sequence of human and virally 
encoded chemokines (using ClustalW 1.83 and an unbranched dendrogram) with the receptor targets of the specific chemok-
ines seen on the right side of the figure. The names of the virally encoded chemokines are highlighted in bold. On the right 
hand side a line is used to illustrate that a specific chemokine is a ligand for a specific chemokine receptor. The line is unbroken 
for endogenous human chemokines and dotted for virally encoded chemokines. The murine lymphotactin has been included to 
illustrate the great similarity between XCL1 and mXCL1.
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Methods
Chemokines
mXCL1, XCL1, vCCL2 were purchased from R&D (Minne-
apolis, MN). Recombinant vCCL3 (GenBank accession
number U93872) was produced as described previously
[10], briefly cell media collected from COS7 cells trans-
fected with the K4.1 gene from HHV8 was collected and
purified on a cation-exchange column followed by reverse
phase HPLC. The elution position of the recombinant
vCCL3 protein as well as the purity was identified with
mass-spectroscopy and NH2-terminal sequence analysis
on an ABI 494 protein sequencer (Perkin-Elmer, CA).
Cloning of mXCR1
The mXCR1 gene was amplified by PCR from a murine
cDNA library and inserted into the pcDNA3.1 vector and
the pTEJ8 vector. Start- and end-primers were designed
from the GenBank accession number NM 011798. Nucle-
otide sequence analysis was performed on an ABI 310
sequence system (Perkin-Elmer, CA) in-house or by MWG
Biotech (Ebersberg, Germany). The human XCR1 gene
inserted in the pcDNA3.1 vector was purchased from the
UMR cDNA Resource Center (Rolla, MO).
Stable cell lines
mXCR1 in pTej was transfected into the murine pre-B cell
line L1.2 and hXCR1 in pcDNA 3.1 was transfected into
the murine pre-B cell line 300.19. Stable transfectants
were obtained after limiting dilution and chemical selec-
tion with G418 and functional clones were selected based
upon their calcium responses to mXCL1 and XCL1,
respectively.
Phosphatidyl-inositol assay
COS-7 cells were transiently transfected by a calcium
phosphate precipitate method with addition of chloro-
quine. Briefly, 2 × 106 COS-7 cells were transfected with
30 ug of cDNA encoding the promiscuous chimeric G-
protein, GαΔ6qi4myr (abbreviated as Gqi4myr), which
allows the Gαi-coupled receptor to couple to the Gαq
pathway (phospholipase C activation measured as PI-
turnover) [16], with or without 20 ug receptor (mXCR1 or
XCR1) cDNA. After transfection, COS-7 cells (2.5 × 104
cells/well) were incubated for 24 hours with 2 μCi of 3H-
myo-inositol in 0.4 ml growth medium per well in 24-
multiwells tissue culture plates. Cells were washed twice
in 20 mM Hepes, pH 7.4, supplemented with 140 mM
NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 10 mM glu-
cose and 0.05% (w/v) bovine serum albumin and were
incubated in 0.4 ml of the same buffer supplemented with
10 mM LiCl at 37°C for 15 minutes. The ligands were sub-
sequently added and incubated for 90 min. In the antago-
nist assay vCCL2 was added 10 min before the agonist to
ensure proper interaction of the receptors with vCCL2.
Cells were extracted by addition of 1 ml 10 mM Formic
acid to each well followed by incubation on ice for 30–60
min. The generated [3H]-inositol phosphates were puri-
fied on AG1-X8 anion-exchange resin (Bio-Rad Laborato-
ries, Hercules, CA). Determinations were made in
duplicate.
Calcium mobilization experiments
L1.2 cells stably transfected with mXCR1 were loaded
with Fura-2AM (Molecular Probes, Eugene, OR) in RPMI
with 1% FCS for 20–30 min. and washed in the same
buffer. Aliqouts were made of 1 × 106 cells, each aliqout
was pelleted and resuspended in 500 ul PBS 1% FCS with
10 mM EGTA. Flourescence was measured on a Jobin
Yvon FlouroMax-2 (Jobin Yvon Spex, Cedex, France) as
the ratio of emission at 490 nm when excited at 340 nm
and 380 nm respectively.
Abbreviations
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